Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

R. Sorio, I. Robieux, E. Galligioni, A. Freschi, A. M. Colussi, D. Crivellari, S. Saracchini, S. Monfardini

Research output: Contribution to journalArticlepeer-review


25 patients older than 65 years with metastatic breast cancer were treated with vinorelbine 30 mg/m2 i.v. days 1 and 8 every 3 weeks; the pharmacokinetics were studied in 10 of them. Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg). These results are similar to those reported in younger patients. No correlation has been found between toxicity, age and drug exposure. We observed 6 partial responses out of 20 evaluable patients despite a relatively low mean dose intensity (67%). Severe neutropenia occurred in 37% of the patients; other side-effects were acceptable. This study does not provide a pharmacokinetic rationale for reducing the dosage of vinorelbine in selected elderly patients.

Original languageEnglish
Pages (from-to)301-303
Number of pages3
JournalEuropean Journal of Cancer
Issue number2
Publication statusPublished - Feb 1997


  • Elderly patients
  • Metastatic breast cancer
  • Pharmacokinetics
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this